MiRNAs-mediated cisplatin resistance in breast cancer.

Abstract

Cisplatin is a widely used chemotherapeutic agent in breast cancer treatments with inevitable rapidly acquired resistance or intrinsically resistance. Enormous evidence points to the bioprocesses of resistant formation consisting of diverse miRNAs direct and indirect actions on relevant encoding genes. In this report, we overview detailed information on the miRNAs effect on cisplatin-induced resistance, including alterations in cell survival, modification of DNA damage response, changes in cellular uptake or efflux of the drug, altered DNA methylation, and perturbations in the miRNA biogenesis pathway. This will provide potential miRNA-targeted strategies for the treatment of breast cancer therapy and requires further clinical application.

• Authors: Xiu Chen, Peng Lu, Ying Wu, Dan-Dan Wang, Siying Zhou, Su-Jin Yang, Hong-Yu Shen, Xiao-Hui Zhang, Jian-Hua Zhao, Jin-Hai Tang
• Journal: Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine (Tumour Biol) Vol. 37 Issue 10 Pg. 12905-12913 (Oct 2016) ISSN: 1423-0380 [Electronic] Netherlands
• PMID: 27448297 (Publication Type: Journal Article, Review)

Chemical References

• Antineoplastic Agents
• MicroRNAs
• Cisplatin

Topics

• Animals
• Antineoplastic Agents (pharmacology)
• Breast Neoplasms (drug therapy, genetics)
• Cisplatin (pharmacology)
• Drug Resistance, Neoplasm (genetics)
• Female
• Gene Expression Regulation, Neoplastic (drug effects)
• Humans
• MicroRNAs (genetics)